We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women

By LabMedica International staff writers
Posted on 10 Jun 2026

Early-onset breast cancer remains a significant concern, with some cases presenting as triple-negative disease, one of its most aggressive forms. More...

Black women face disproportionately elevated risks of developing and dying from breast cancer diagnosed at or before age 50. Although genetic screening can clarify inherited risk and guide care, it remains underused in this group. New findings now identify the genes most commonly harboring variants among young Black women with invasive breast cancer.

Vanderbilt University Medical Center (Nashville, TN, USA) researchers contributed to a study that assessed hereditary cancer genetic testing among 686 young Black women with invasive breast cancer diagnosed in Florida and Tennessee. The technology involves testing genes known to influence inherited cancer risk to determine whether individuals carry variants associated with breast and/or ovarian cancer. Genes examined in the analysis included BRCA1, BRCA2, PALB2, and ATM, among others.

In the cohort diagnosed at age 50 or younger during 2005–2018, 15.3% of women carried a gene variant with a suspected link to breast and/or ovarian cancer. Most of these variants occurred in BRCA1 and BRCA2, with fewer identified in PALB2, ATM, and other genes. A family history of breast cancer was common among women with variants in BRCA1, BRCA2, and PALB2.

Triple-negative breast cancers were most often observed in women with BRCA1 variants. Most women with BRCA1 variants were diagnosed at or below age 40, whereas the age at diagnosis was more evenly distributed up to age 50 for women with variants in other genes. The authors note that these findings underscore the importance of genetic testing for young Black women, a group that is less likely to receive such screening compared with other racial and ethnic groups. The study is published in Cancer on June 8, 2026.

"We must test at-risk women across all populations—testing is essential to personalize treatment strategies and enable life-saving prevention for future cancers, and it may empower at-risk family members to get tested so they too can benefit from this information," said Tuya Pal, MD, senior author at Vanderbilt University Medical Center. "Equitable access to inherited cancer testing ensures that all women, regardless of race, can benefit from precision medicine and take control of their genetic health."

Related Links
Vanderbilt University Medical Center


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.